| Literature DB >> 34735901 |
Yimin Chen1, Thanh N Nguyen2, Jack Wellington3, Mohammad Mofatteh4, Weiping Yao5, Zhaohui Hu6, Qiuping Kuang1, Weijuan Wu1, Xuejun Wang1, Yu Sun1, Kexun Ouyang7, Junmiao Xu1, Weiquan Huang8, Shuiquan Yang9.
Abstract
OBJECTIVES: This study aims to evaluate shortening door-to-needle time of intravenous recombinant tissue plasminogen activator of acute ischemic stroke patients by multidisciplinary collaboration and workflow optimization based on our hospital resources.Entities:
Keywords: Acute ischemic stroke; COVID-19 pandemic; Door-to-Needle Time; Thrombolysis
Mesh:
Substances:
Year: 2021 PMID: 34735901 PMCID: PMC8526426 DOI: 10.1016/j.jstrokecerebrovasdis.2021.106179
Source DB: PubMed Journal: J Stroke Cerebrovasc Dis ISSN: 1052-3057 Impact factor: 2.136
Baseline characteristics of patients between pre-intervention and post-intervention.
| Total number | pre-interventio | post-interventio | t/z/χ² | |
|---|---|---|---|---|
| 128 | 135 | |||
| Mean age (SE) | 62.27 ± 12.89 | 65.20 ± 12.71 | -1.854 | 0.07 |
| Men, n (%) | 90 (70.31) | 90 (66.67) | 0.404 | 0.53 |
| NIHSS score, median (IQR) | 6.0 (3.0–12.0) | 6.0 (3.0–12.0) | -0.607 | 0.54 |
| Hypertension, | 91 (71.1) | 95 (70.4) | 0.06 | 0.81 |
| Atrial fibrillation, | 13 (10.48) | 18(13.43) | 0.53 | 0.47 |
| Diabetes mellitus, | 13 (10.32) | 24 (17.91) | 3.067 | 0.08 |
| Previous stroke/TIA, | 8 (6.35) | 28 (20.90) | 11.519 | 0.001 |
| Previous coronary heart disease, | 16 (12.70) | 15 (11.19) | 0.14 | 0.708 |
| Hyperlipidemia, | 36 (28.57) | 43 (32.09) | 0.38 | 0.538 |
| Thrombectomy, | 6 (4.84) | 15 (11.19) | 3.479 | 0.062 |
Outcome of two groups.
| Total number | pre-intervention | post-intervention | t/z/χ² | |
|---|---|---|---|---|
| 128 | 135 | |||
| median DNT | 57.0 (45.3–77.8) | 37.0 (29.0–49.0) | -7.794 | < 0.001 |
| DNT≤ 30 min | 6 (4.7%) | 40 (29.6%) | 28.324 | < 0.001 |
| DNT≤ 45 min | 32 (25%) | 96 (71.1%) | 55.92 | < 0.001 |
| DNT≤ 60 min | 73 (57.0%) | 116 (85.9%) | 27.129 | < 0.001 |
| DNT> 60 min | 55 (43.0%) | 19 (14.1%) | 27.129 | < 0.001 |
| Median ODT | 85.0 (59.0–120.0) | 86.5 (52.5–141.3) | -0.69 | 0.49 |
| Median DCT | 13.0 (7.0–22.5) | 15.0(10.0–19.0) | -1.058 | 0.29 |
| DCT≤ 20 min | 94 (73.4%) | 109 (80.7%) | 1.99 | 0.158 |
| Median CNT | 45.0 (34.5–58.0) | 23.0 (17.0–31.8) | -8.7 | < 0.001 |
| Median ONT | 154.0 (120.0–186.0) | 138.5 (98.0–184.5) | -2.289 | 0.022 |
| HT | 7 (5.79%) | 6 (4.48%) | 0.225 | 0.635 |
| sICH | 4 (3.1%) | 3 (2.22%) | 0.005 | 0.943 |
ODT: onset-to-door time, DCT: door-to-CT time, DNT: door-to-needle time, CNT: CT-to-needle time, ONT: onset-to-needle time, HT: Hemorrhagic Transformation, sICH: symptomatic intracranial hemorrhage.
Median DNT, ODT, DCT, CNT and ONT from 2018 January to 2020 September.
| Time | 2018 | 2019 | 2019 | 2019 | 2019 | 2020 | 2020 | 2020 |
|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | ||
| Median DNT | 68.0 (53.50-93.25) | 73.5 (46.25-86.00) | 50.0 (44.50-59.50) | 57.0 (46.00-80.00) | 50.0 (40.00-57.75) | 50.5 (38.00-82.00) | 35.0 (30.00-46.25) | 32.0 (25.00-43.00) |
| Median ODT | 67.5 (50.00-106.50) | 75.0 (39.75-111.00) | 85.0 (60.00-120.00) | 120.0 (64.00-150.00) | 83.0 (62.00-109.50) | 69.0 (48.00-138.50) | 106.5 (60.75-141.25) | 79.0 (49.00-160.00) |
| Median DCT | 19.0 (9.00-25.00) | 13.5 (8.50-26.75) | 11.0 (7.00-16.00) | 10.0 (7.00-26.00) | 13.0 (9.25-22.25) | 15.0 (10.00-21.00) | 16.0 (11.00-19.75) | 14.0 (10.00-17.75) |
| Median CNT | 50.0 (41.00-70.00) | 51.5 (38.00-74.75) | 38.0 (30.00-51.00) | 47.0 (35.00-58.00) | 36.5 (29.00-45.00) | 31.0 (24.00-61.00) | 21.0 (17.50-26.50) | 19.5 (12.25-27.00) |
| Median ONT | 155.0 (129.75-177.75) | 148.5 (120.50-195.25) | 152.0 (111.75-184.75) | 186.0 (133.00-230.00) | 136.5 (99.50-172.50) | 136.0 (102.50-185.50) | 142.5 (95.75-192.50) | 123.0 (83.00-184.00) |
Q1= first quarter of the year.Q2= second quarter of the year. Q3= third quarter of the year. Q4= fourth quarter of the year. DNT, door-to-needle-time; ODT, onset-to-door time; DCT, door-to-CT-time; CNT, CT-to-needle-time.
Fig. 1DNT meeting rate from 2018 to Q3 of 2020.
Fig. 2Median DNT from 2018 to Q3 of 2020.
Fig. 3A - Median ODT from 2018 to Q3 of 2020; B - Median DCT from 2018 to 2020 Q3; C - Median CNT from 2018 to 2020 Q3; D - Median ONT from 2018 to 2020 Q3.